|17. Switch to a TNFi biologic monoclonal antibody biologic over an IL-12/23i biologic (PICO 61)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration.|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration.|
|18. Switch to an IL-12/23i biologic over switching to an IL-17i biologic (PICO 60)|Moderate (50)|